Recent Updates
Recently added Catalysts

Laropiprant

Phase 1

Rosacea | Small molecule | Dermatology |Merck & Company, Inc.|Last Updated: Mar 25, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment60

FDA Designations

No designations recorded

Clinical trial landscape

Laropiprant · 1 trial · 1 indication

Phase 1 1
NCT01451619A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)Rosacea
COMPLETED60 Analytics
PHASE1COMPLETED
A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)
Rosacea
NCT0145161960
Unlock trial analytics

Study Endpoints

Primary Endpoints

Change in Clinician's Erythema Assessment (CEA) Scale Score from Baseline
Baseline and Week 4

Secondary Endpoints

Change in Patient Self Assessment (PSA) Score from Baseline
Baseline and Week 4
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
LaropiprantEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
LaropiprantDRUGOne 100-mg tablet orally once daily for 4 weeks
Placebo for LaropiprantDRUGOne tablet orally once daily for 4 weeks
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Moderate to severe erythematotelangiectatic rosacea with moderate to severe erythema of facial lesion * Generally healthy excluding rosacea * Presence of telangiectasia * Five or less facial inflammatory lesions * Able to restrict diet in order to avoid foods/drinks (including...

Unlock Eligibility Criteria

Frequently asked questions about Laropiprant

What is Laropiprant used for?

Laropiprant is an investigational small molecule being studied for hypercholesterolemia and rosacea. In hypercholesterolemia, it was evaluated for its effect on cholesterol levels, and in rosacea, it was studied in participants with moderate to severe erythematotelangiectatic rosacea. It is not approved and remains in clinical development.

Who makes Laropiprant?

Laropiprant is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company has sponsored clinical trials of the drug for hypercholesterolemia and rosacea.

What phase is Laropiprant in?

Laropiprant is in Phase 1 clinical development, based on a completed Phase 1 trial in rosacea. It has also been studied in a completed Phase 3 trial for hypercholesterolemia. The drug is investigational and not FDA approved.

What clinical trials is Laropiprant in?

Laropiprant has been studied in two completed trials. NCT00536510 was a Phase 3 trial in hypercholesterolemia and hyperlipidemia with 646 participants. NCT01451619 was a Phase 1 trial in moderate to severe erythematotelangiectatic rosacea with 60 participants.

Is Laropiprant the same as MK-0524?

Yes, Laropiprant is also known as MK-0524. In clinical trials, it has been referred to by this alternative name, such as in the study of Laropiprant (MK-0524) in participants with rosacea.